Aardvark Therapeutics, Inc. Common Stock AARD Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $62.44M+136% | $47.05M-23.7% | $39.29M— | $26M— | $26.5M— | ||
| $28.76M-76.9% | $62.98M+424% | $87.07M— | $115.82M— | $124.76M— | ||
| $2.38M-27.7% | $1.86M+292% | $2.86M— | $2.95M+6,042% | $3.29M+892% | ||
| $93.58M-39.5% | $111.89M+50.9% | $129.21M— | $144.77M— | $154.55M— | ||
| $269K-57.2% | $355K-51.7% | $439K— | $522K— | $628K— | ||
| $4.74M+157% | $4.94M+87.5% | $3.58M— | $2.19M— | $1.84M— | ||
| $98.59M-37.2% | $117.18M+51.2% | $133.23M— | $147.48M— | $157.03M— | ||
| $4.49M+75.8% | $2.07M-9.8% | $4.44M+861% | $5.06M+697% | $2.56M+674% | ||
| $6.78M+124% | $8.04M+251% | $5.86M— | $4.84M— | $3.03M— | ||
| $336K-13.8% | $441K+30.5% | $429K— | $417K— | $390K— | ||
| $11.6M+94.2% | $10.55M+114% | $10.74M— | $10.31M— | $5.98M— | ||
| —— | $0-100% | $116K— | $228K— | $336K— | ||
| —— | $441K— | —— | —— | —— | ||
| —— | $0-100% | $0— | $12K— | $24K— | ||
| $11.6M+83.1% | $10.55M+95.6% | $10.85M— | $10.55M— | $6.34M— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $224.48M+2.8% | $222.47M+5,939% | $220.62M— | $218.93M— | $218.28M— | ||
| -$137.51M-103% | -$115.92M-98.7% | -$98.32M— | -$82M— | -$67.64M— | ||
| $14K-68.2% | $81K— | $82K— | -$3K— | $44K— | ||
| $86.99M-42.3% | $106.63M+295% | $122.38M+365% | $136.93M+424% | $150.69M+508% | ||
| $98.59M-37.2% | $117.18M+51.2% | $133.23M— | $147.48M— | $157.03M— | ||
| $4.74M+157% | $4.94M+87.5% | $3.58M— | $2.19M— | $1.84M— | ||
| $269K-57.2% | $355K-51.7% | $439K— | $522K— | $628K— | ||
| $269K-57.2% | $355K-51.7% | $439K— | $522K— | $628K— | ||
| $4.74M+157% | $4.94M+87.5% | $3.58M— | $2.19M— | $1.84M— | ||
| $28.76M-76.9% | $62.98M+424% | $87.07M— | $115.82M— | $124.76M— | ||
| $269K-57.2% | $355K-51.7% | $439K— | $522K— | $628K— | ||
| $4.74M+157% | $4.94M+87.5% | $3.58M— | $2.19M— | $1.84M— | ||
| $6.78M+124% | $8.04M+251% | $5.86M— | $4.84M— | $3.03M— | ||
| $6.78M+124% | $8.04M+251% | $5.86M— | $4.84M— | $3.03M— | ||
| $336K-53.7% | $441K-43.4% | $545K— | $645K— | $726K— | ||
| $224.48M+2.8% | $222.47M+5,939% | $220.62M— | $218.93M— | $218.28M— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aardvark Therapeutics, Inc. Common Stock's total assets?
- Aardvark Therapeutics, Inc. Common Stock (AARD) holds $98.6M in total assets, down 37.2% year over year.
- How much debt does Aardvark Therapeutics, Inc. Common Stock have?
- Aardvark Therapeutics, Inc. Common Stock carries $336.0K in total debt against $87.0M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Aardvark Therapeutics, Inc. Common Stock have?
- Aardvark Therapeutics, Inc. Common Stock holds $62.4M in cash and equivalents.
- Can Aardvark Therapeutics, Inc. Common Stock cover its short-term obligations?
- Its current ratio is 8.06 — current assets exceed current liabilities.
- Where does Aardvark Therapeutics, Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.